Quick Answer
Profound Medical Corp. reported Total Revenue of $16.10 million for fiscal year 2025.
Profound Medical Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $16.10M +50.7% |
$10.68M +48.4% |
$7.20M | — |
| Net Income | -$42.57M -53.0% |
-$27.82M +1.8% |
-$28.32M | — |
| Diluted EPS | $1.41 +25.9% |
$1.12 -16.4% |
$1.34 | — |
| Total Assets | $77.47M +10.3% |
$70.23M +59.8% |
$43.96M | — |
| Cash and Equivalents | $59.72M +8.8% |
$54.91M +109.5% |
$26.21M | — |
| Long-Term Debt | $4.50M +53.9% |
$2.92M -41.5% |
$5.00M | — |
| Stockholders Equity | $66.43M +10.0% |
$60.42M +93.5% |
$31.22M -40.6% |
$52.60M |
| R&D Expense | $20.60M +21.4% |
$16.96M +17.6% |
$14.42M | — |
| Operating Income | -$41.25M -24.8% |
-$33.06M -15.4% |
-$28.65M | — |
| Gross Profit | $11.39M +61.9% |
$7.04M +63.2% |
$4.31M | — |
| Shares Outstanding | 36.29M +20.8% |
30.04M +40.6% |
21.37M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.29M | +86.8% | +139.2% |
| Net Income | September 30, 2025 | -$7.98M | +14.8% | +49.2% |
| Diluted EPS | September 30, 2025 | $0.26 | -31.6% | -50.0% |
| Total Assets | September 30, 2025 | $42.30M | — | -14.8% |
| Cash and Equivalents | September 30, 2025 | $24.83M | — | -29.5% |
| Long-Term Debt | June 30, 2025 | $4.46M | — | -0.5% |
| Stockholders Equity | September 30, 2025 | $32.14M | +4.6% | -18.1% |
| R&D Expense | September 30, 2025 | $5.42M | +30.1% | -11.2% |
| Operating Income | September 30, 2025 | -$8.91M | +0.9% | +35.4% |
| Gross Profit | September 30, 2025 | $3.93M | +119.9% | +143.0% |
| Shares Outstanding | September 30, 2025 | 30.19M | — | +0.5% |
- Profound Medical Corp. reported Total Revenue of $16.10 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +50.7% in Total Revenue compared to the prior fiscal year.
- Profound Medical Corp. reported Net Income of -$42.57 million for fiscal year 2025.
- Profound Medical Corp. showed a decrease of -53.0% in Net Income compared to the prior fiscal year.
- Profound Medical Corp. reported Diluted EPS of $1.41 per share for fiscal year 2025.
- Profound Medical Corp. showed an increase of +25.9% in Diluted EPS compared to the prior fiscal year.
- Profound Medical Corp. reported Total Assets of $77.47 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +10.3% in Total Assets compared to the prior fiscal year.
- Profound Medical Corp. reported Cash and Equivalents of $59.72 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +8.8% in Cash and Equivalents compared to the prior fiscal year.
- Profound Medical Corp. reported Long-Term Debt of $4.50 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +53.9% in Long-Term Debt compared to the prior fiscal year.
- Profound Medical Corp. reported Stockholders Equity of $66.43 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +10.0% in Stockholders Equity compared to the prior fiscal year.
- Profound Medical Corp. reported R&D Expense of $20.60 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +21.4% in R&D Expense compared to the prior fiscal year.
- Profound Medical Corp. reported Operating Income of -$41.25 million for fiscal year 2025.
- Profound Medical Corp. showed a decrease of -24.8% in Operating Income compared to the prior fiscal year.
- Profound Medical Corp. reported Gross Profit of $11.39 million for fiscal year 2025.
- Profound Medical Corp. showed an increase of +61.9% in Gross Profit compared to the prior fiscal year.
- Profound Medical Corp. reported Shares Outstanding of 36.29 million shares for fiscal year 2025.
- Profound Medical Corp. showed an increase of +20.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: